GSK plc (NYSE:GSK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of GSK plc (NYSE:GSK) have earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and three have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $43.25.

GSK has been the topic of a number of research reports. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th.

Institutional Trading of GSK

Several institutional investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC grew its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Primecap Management Co. CA increased its holdings in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares in the last quarter. Provident Trust Co. boosted its stake in GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after purchasing an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its holdings in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK opened at $35.20 on Friday. The company has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 1.37 and a beta of 0.63. The business has a 50 day moving average price of $34.04 and a 200 day moving average price of $37.71. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.